All Chimeric Antigen Receptors (CARs) articles – Page 3
-
NewsCancer-killing T cells enhanced by engineered bacteria
Bacteria programmed to paint targets on solid tumours for T cells to see eliminates the need for specific antigens.
-
WebinarComplete aggregate and particle characterisation of protein, gene and cell therapies
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
-
WebinarComplete CAR-T workflow solutions for research
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
-
ArticleNext-generation CAR T cells
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
-
ArticleDrug Target Review Cell and Gene Therapy eBook 2023
Download your FREE ebook, featuring articles about cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and advancements in gene editing.
-
ArticleDrug Target Review - Issue 2 2023
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
-
NewsCustomising T cell-based immunotherapies to treat cancers
US researchers usings a ‘SNAP’ receptor system can customise immunotherapies for targeted treatments of cancer and other diseases.
-
WebinarAccelerating biologics discovery via antibody library and reaching IND faster with cell line development
The application of Fab and VHH naïve library to expedite the antibody discovery against tumor-associated antigen for CAR-T, ADC and bispecific antibody.
-
NewsWhat is the key source of T cell exhaustion?
US discovery opens the way to drugs that can prevent T cell therapies from losing their potency over time.
-
NewsImproving immunotherapy against brain cancer
US scientists suggest that anti-angiogenesis drugs could improve the function and delivery of CAR-T cell therapy.
-
NewsNew immunotherapy approach holds promise for ovarian cancer
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
-
ArticleDeveloping state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
-
ArticleAllogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
-
NewsScientists identify a biomarker that predicts CAR T-cell therapy efficacy
Combining AI with cutting-edge flow cytometry and massive sequencing technologies, researchers describe CAR T cell characteristics that determine their therapeutic capacity for the first time.
-
NewsLife-saving approach may overcome persistent obstacles to cell transplantation and immunotherapy
In their study, researchers duped antibodies with a decoy to prevent rejection of transplanted cells.
- Previous Page
- Page1
- Page2
- Page3
- Next Page